TuHURA Biosciences develops experimental cancer treatments for patients whose tumors resist immunotherapy, based in Tampa, Florida. HURA reports earnings on Fri, Nov 13, 2026.
Prices, price targets and earnings estimates for HURA are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in HURA in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HURA is in one of them and how their past HURA trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About TuHURA Biosciences
TuHURA Biosciences is a clinical stage company based in Tampa, Florida, that develops cancer treatments. Its lead candidate, IFx-2.0, is injected into tumors and is designed to make cancer cells look like bacteria so the immune system attacks them. It is aimed at patients whose cancers do not respond to checkpoint inhibitor drugs. The company is also developing TBS-2025, an antibody for acute myeloid leukemia, and early-stage drugs that target cells which suppress the immune system. Its candidates are not yet approved for sale.
